14,897 Shares in Pyxis Oncology, Inc. (NASDAQ:PYXS) Bought by Intech Investment Management LLC

Intech Investment Management LLC bought a new position in shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 14,897 shares of the company’s stock, valued at approximately $55,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Fullcircle Wealth LLC bought a new position in shares of Pyxis Oncology during the 2nd quarter valued at about $40,000. SG Americas Securities LLC bought a new position in Pyxis Oncology in the third quarter valued at approximately $58,000. The Manufacturers Life Insurance Company acquired a new position in shares of Pyxis Oncology in the second quarter valued at approximately $65,000. Cetera Advisors LLC acquired a new position in shares of Pyxis Oncology in the first quarter valued at approximately $100,000. Finally, Schulhoff & Co. Inc. increased its position in shares of Pyxis Oncology by 90.9% during the second quarter. Schulhoff & Co. Inc. now owns 42,000 shares of the company’s stock worth $139,000 after acquiring an additional 20,000 shares in the last quarter. 39.09% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, CFO Pamela Ann Connealy acquired 88,850 shares of the business’s stock in a transaction on Tuesday, November 26th. The stock was purchased at an average cost of $1.96 per share, for a total transaction of $174,146.00. Following the completion of the transaction, the chief financial officer now directly owns 1,199,143 shares of the company’s stock, valued at approximately $2,350,320.28. The trade was a 8.00 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 9.80% of the stock is owned by insiders.

Pyxis Oncology Trading Down 1.8 %

NASDAQ:PYXS opened at $1.67 on Monday. The stock has a market capitalization of $99.31 million, a PE ratio of -1.62 and a beta of 1.00. The firm has a fifty day simple moving average of $3.28 and a 200 day simple moving average of $3.44. Pyxis Oncology, Inc. has a 1-year low of $1.64 and a 1-year high of $6.85.

Analyst Ratings Changes

A number of equities analysts recently weighed in on PYXS shares. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 target price on shares of Pyxis Oncology in a research note on Thursday, November 21st. Stephens began coverage on Pyxis Oncology in a research report on Friday, November 8th. They set an “overweight” rating and a $13.00 price objective for the company. William Blair lowered Pyxis Oncology from an “outperform” rating to a “market perform” rating in a research report on Thursday, November 21st. Finally, Royal Bank of Canada upped their price target on Pyxis Oncology from $7.00 to $10.00 and gave the stock an “outperform” rating in a research report on Thursday, November 21st. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $10.00.

Pyxis Oncology Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.